目的 探讨黄芪注射液联合维立西呱治疗慢性心力衰竭的临床疗效。方法 回顾性分析2024年1月—2024年12月在临清市人民医院治疗的128例慢性心力衰竭患者的病例资料，按治疗方案不同分为对照组和治疗组，每组各64例。对照组口服维立西呱片，2.5 mg/次，1次/d。在此基础上，治疗组静脉滴注黄芪注射液，30 mL加入250 mL生理盐水，60 min内完成，1次/d。两组患者连续治疗7 d。观察两组患者临床疗效，比较治疗前后两组患者心功能相关指标左室射血分数（LVEF）、每搏输出量（SV）、心脏指数（CI）和6 min步行距离（6MWD）水平，明尼苏达心力衰竭生活质量问卷（MLHFQ）、焦虑自评量表（SAS）和抑郁自评量表（SDS）评分，及凝血酶原时间（PT）、血浆纤维蛋白原（FIB）、中性粒细胞与淋巴细胞比值（NLR）、C反应蛋白（CRP）和N末端B型利钠肽原（NT-proBNP）水平。结果 治疗后，治疗组总有效率为95.31%，明细高于对照组84.38%（P＜0.05）。治疗后，两组LVEF、SV、CI、6MWT和PT均较治疗前显著增加（P＜0.05），两组MLHFQ、SAS、SDS评分及血浆FIB、NLR和血清CRP、NT-proBNP水平均显著降低（P＜0.05），且治疗组这些指标改善情况明显好于对照组（P＜0.05）。结论 黄芪注射液联合维立西呱治疗慢性心力衰竭疗效显著，能有效改善心功能，控制凝血异常及炎症反应，提升患者生活质量，缓解焦虑、抑郁等不良心理状态。

Objective To investigate the clinical efficacy of Huangqi Injection combined with vericiguat in treatment of chronic heart failure. Methods The clinical data of patients (128 cases) with chronic heart failure in Linqing People’s Hospital from January 2024 to December 2024 were analyzed retrospectively. They were divided into control and treatment group based on different treatments, and each group had 64 cases. Patients in the control group were po administered with Vericiguat Tablets, 2.5 mg/time, once daily. Patients in the treatment group were iv administered with Huangqi Injection on the basis of the control group, 30 mL added into 250 mL normal saline within 60 min, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluations were evaluated, and the cardiac function related indexes LVEF, SV, CI and 6MWT levels, the scores of MLHFQ, SAS and SDS, and the levels of PT, FIB, NLR, CRP and NT-proBNP in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 95.31%, which was higher than 84.38% in the control group (P < 0.05). After treatment, LVEF, SV, CI, 6MWT, and PT in two groups were significantly increased compared with before treatment (P < 0.05). The MLHFQ, SAS, SDS scores and plasma FIB, NLR, and serum CRP and NT-proBNP levels in two groups were significantly decreased (P < 0.05), and the improvement of these indicators in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Huangqi Injection combined with viaciguat has significant curative effects on chronic heart failure. It can effectively improve cardiac function, control coagulation abnormalities and inflammatory reactions, improve patients 'quality of life, and relieve anxiety, depression and other adverse mental states.

R972

山东省医药卫生科技项目（202404071033）